Thomas Arun Z, Adibi Mehrad, Borregales Leonardo D, Hoang Ly N, Tamboli Pheroze, Jonasch Eric, Tannir Nizar M, Matin Surena F, Wood Christopher G, Karam Jose A
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
J Urol. 2015 Aug;194(2):316-22. doi: 10.1016/j.juro.2015.02.2943. Epub 2015 Mar 7.
Isolated local retroperitoneal recurrence after radical nephrectomy for renal cell carcinoma poses a therapeutic challenge. We investigated outcomes in patients with localized retroperitoneal recurrence treated with surgical resection.
This was a retrospective, single institutional study of 102 patients with retroperitoneal recurrence treated with surgery from 1990 to 2014. Demographics, clinical and pathological features, location of retroperitoneal recurrence and perioperative complications are reported using descriptive statistics. We studied recurrence-free and cancer specific survival using univariate and multivariate analyses.
Median age at retroperitoneal recurrence diagnosis was 55 years (IQR 49-64). Cancer was pT3-4 in 62 patients (60.8%) and pN1 in 20 (19.6%). No patients had distant metastatic disease at retroperitoneal recurrence surgery. Median time from nephrectomy to retroperitoneal recurrence diagnosis was 19 months (IQR 5-38.8). The median size of the resected retroperitoneal recurrence was 4.5 cm (IQR 2.7-7). Median followup after recurrence surgery was 32 months (IQR 16-57). Metastatic progression was observed in 60 patients (58.8%) postoperatively. Neoadjuvant and salvage systemic therapy was administered in 46 (45.1%) and 48 patients (47.1%), respectively. On multivariate analysis pathological nodal stage at original nephrectomy and maximum diameter of retroperitoneal recurrence were identified as independent risk factors for cancer specific death.
Clinicopathological factors at nephrectomy as well as retroperitoneal recurrence surgery are important prognosticators. Aggressive surgical resection offers potential cure in a substantial number of patients with retroperitoneal recurrence with acceptable complications and still has a dominant role in the management of isolated locally recurrent RCC.
肾细胞癌根治性肾切除术后孤立性局部腹膜后复发带来了治疗挑战。我们研究了接受手术切除治疗的局限性腹膜后复发患者的预后。
这是一项回顾性单机构研究,纳入了1990年至2014年接受手术治疗的102例腹膜后复发患者。使用描述性统计报告人口统计学、临床和病理特征、腹膜后复发部位及围手术期并发症。我们采用单因素和多因素分析研究无复发生存率和癌症特异性生存率。
腹膜后复发诊断时的中位年龄为55岁(四分位间距49 - 64岁)。62例患者(60.8%)癌症为pT3 - 4期,20例(19.6%)为pN1期。在腹膜后复发手术时,无患者有远处转移疾病。从肾切除到腹膜后复发诊断的中位时间为19个月(四分位间距5 - 38.8个月)。切除的腹膜后复发灶的中位大小为4.5 cm(四分位间距2.7 - 7 cm)。复发手术后的中位随访时间为32个月(四分位间距16 - 57个月)。术后60例患者(58.8%)出现转移进展。分别有46例(45.1%)和48例患者(47.1%)接受了新辅助和挽救性全身治疗。多因素分析显示,初次肾切除时的病理淋巴结分期和腹膜后复发的最大直径是癌症特异性死亡的独立危险因素。
肾切除时的临床病理因素以及腹膜后复发手术是重要的预后指标。积极的手术切除可为大量腹膜后复发患者带来潜在治愈机会,并发症可接受,在孤立性局部复发性肾细胞癌的治疗中仍起主导作用。